logo
Freedom Holding Corp. Reports Fiscal Year 2025 Financial Results

Freedom Holding Corp. Reports Fiscal Year 2025 Financial Results

Almaty, Kazakhstan, June 14th, 2025, FinanceWire
Freedom Holding Corp. (NASDAQ: FRHC), the diversified financial group with operations spanning 22 countries, today reported financial results for the fiscal year ended March 31, 2025, highlighting continued growth across core segments and meaningful progress on its digital ecosystem strategy.
Revenue for the year increased by 23% to $2.05 billion, up from $1.67 billion the previous year. The company delivered strong operational performance.Total assets increased to $9.9 billion, and customer growth remained strong across all sectors.
'Our 2025 results show that the strategy we've been building for years is paying off,' said Timur Turlov, founder and CEO of Freedom Holding Corp. 'We are transitioning from a collection of financial products to a unified ecosystem that touches nearly every aspect of our customers' financial lives. We're proud of the growth we've achieved, especially in our core businesses, and excited about what lies ahead.'
Fiscal 2025 Highlights
The company delivered strong operational growth, with total revenue reaching $2.05 billion — a 23% increase on the $1.67 billion recorded the previous year. This growth was driven by increased activity in brokerage and insurance segments, as well as higher interest income from margin and customer loans, reflecting the continued expansion of the company's diverse financial ecosystem.
Fee and commission income totaled $505.0 million, marking a 15% increase from $440.3 million in fiscal 2024. This growth was primarily fueled by a 29% increase in income from brokerage services, reaching $430.1 million, supported by an expanding retail customer base.
Interest income increased to $864.5 million, a 4% rise on the previous year. This was driven by increased margin lending to retail clients and an expanded loan portfolio at Freedom Bank KZ. Margin loan interest increased by 21%, while interest from customer loans grew by 18%. Increased returns from available-for-sale securities also contributed to gains, though income from trading securities declined amid market volatility.
Earnings per share were $1.43 (basic) and $1.40 (diluted), compared to $6.37 (basic) and $6.33 (diluted) in fiscal 2024. Net income amounted to $84.5 million.
Brokerage accounts reached 683,000, marking a 29% year-on-year increase, while active accounts surged by 57% to surpass 151,000. The number of bank clients more than doubled to 2.5 million, and the number of insurance customers reached 1.17 million, reflecting the rising demand for integrated financial services.
The insurance segment was one of the year's top performers, with underwriting income up 134% to $617.6 million amid robust demand for pension and accident insurance products. The brokerage division generated $717.3 million in revenue, with fee and commission income, as well as interest income, remaining strong. The company's banking segment posted $506.1 million in revenue, while the 'Other' segment — which includes lifestyle, telecom, and payment services — saw revenue increase 72% to $144 million, buoyed by contributions from e-commerce platform Arbuz, ticketing service Aviata, and newly acquired SilkNetCom LLP.
Freedom Holding took further bold steps to diversify its operations beyond finance. In 2024, it expanded its telecommunications business under the name Freedom Telecom and launched new media projects. These ventures form part of a broader plan to develop a comprehensive digital ecosystem centered on the company's flagship Freedom SuperApp, which integrates investing, banking, payments, and lifestyle services on a single platform.
"This year is a period of large-scale investments in the development of the holding's ecosystem for us. We are reinvesting a significant portion of the income from our key business areas into strengthening and growing the group's companies. This strategy is already yielding results: our market position is strengthening, and our presence is expanding. At the same time, we continue to invest in business development in new regions — both where licenses have already been obtained and where they are still in the process of being acquired," noted Timur Turlov.
The holding continued to provide sponsorship support to various initiatives: the Kazakhstan Chess and Tennis Federations, the Competitive Programming Federation, the Junior Football League of Kazakhstan, and other organizations.
The company's focus remains on scaling its technology, expanding geographically, and deepening customer experience through artificial intelligence and product personalization.
'We believe connected ecosystems will define the next era of finance,' said Turlov. 'By combining traditional financial stability with tech-enabled innovation, we're building something that goes far beyond banking or brokerage. We're building infrastructure for how people live, spend, save, and grow.'
About Freedom Holding Corp.
Freedom Holding Corp. provides financial services in 22 countries, including Kazakhstan, the United States, Cyprus, Poland, Spain, Uzbekistan, and Armenia. The Company's principal executive office is located in New York City.
In Kazakhstan, Freedom is actively developing its financial and digital ecosystem, which includes Freedom Bank, Freedom Broker, the insurance companies Freedom Life and Freedom Insurance, as well as a lifestyle segment that features Arbuz.kz, Freedom Ticketon, and Aviata.
Freedom Holding Corp. shares are traded on the U.S. technology exchange NASDAQ, the Kazakhstan Stock Exchange (KASE), and the Astana International Exchange (AIX) under the ticker symbol FRHC. The Company has a market capitalization exceeding $8 billion as of March 31, 2025. Freedom Holding Corp. is regulated by the U.S. Securities and Exchange Commission (SEC).
Public Relations
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Palantir Stock Is Up 478% in a Year. Here's Why There's Still More Room to Run.
Palantir Stock Is Up 478% in a Year. Here's Why There's Still More Room to Run.

Yahoo

timean hour ago

  • Yahoo

Palantir Stock Is Up 478% in a Year. Here's Why There's Still More Room to Run.

Key Points Palantir Technologies now ranks in the top 25 of the most valuable companies in the world. Its Artificial Intelligence Platform (AIP) is wildly popular for commercial and government clients. 10 stocks we like better than Palantir Technologies › There are probably few investors out there who are more satisfied than those who bought Palantir Technologies (NASDAQ: PLTR) stock early in its run. The artificial intelligence (AI) company is blowing other stocks out of the water these days, with its stock up 478% in the last year and more than doubling in 2025. Palantir is now one of the world's top 25 most valuable companies, ahead of such blue chip names as Procter & Gamble and Bank of America. Palantir's run is fueled by the adaptation of its Artificial Intelligence Platform (AIP) by government and commercial clients, fueling dramatic growth in both revenue and earnings. And with Palantir set to report second-quarter earnings on Aug. 4, there are plenty of reasons to believe that this run is far from over. How Palantir is making money Palantir already had two AI-powered platforms. Its Gotham platform is prized by governments and defense agencies to gather information from multiple sources, identify targets, and make real-time assessments to provide insights about battlefield situations. Palantir is recognized for helping the U.S. military track down 9/11 mastermind Osama bin Laden in 2011. Then you have the Foundry platform used by Palantir's commercial clients. Foundry helps clients manage supply chains and inventory, automate workflows, and optimize operations. The AIP platform made both of these powerful tools better and easier to use because AIP allows users to make detailed queries, and then it generates responses using generative AI. And the results are evident in the massive gains the company is seeing: Since rolling out AIP in April 2023, Palantir's revenues have gone through the roof. Year Revenue Profit (Loss) Earnings per Share 2021 $1.54 billion ($520.3 million) ($0.27) 2022 $1.90 billion ($161.2 million) ($0.18) 2023 $2.22 billion $217.3 million $0.10 2024 $2.86 billion $467.9 million $0.21 2025 (projected) $3.90 billion Image source: Palantir Technologies. In the first quarter of 2025, the company reported revenue of $884 million, up 39% from a year ago. U.S. commercial revenue jumped 71% from a year ago to $255 million, and U.S. government revenue was up 45% from a year ago to $373 million. The stock is by far outperforming the biggest companies on the planet, as well as the S&P 500 and the Nasdaq Composite. What can we expect from Palantir next? The second quarter is expected to be another blowout quarter. The company is continuing to reel in work, including contracts with the Navy to improve ship production and fleet readiness and a partnership with Accenture (NYSE: ACN) to develop AI solutions for federal agencies. On the commercial side, Palantir signed a deal with The Nuclear Company to develop and modernize nuclear power plants, as well as an agreement with The Joint Commission to use AI to manage accreditation and certification standards at hospitals and healthcare organizations. Palantir issued guidance for second-quarter revenue of $934 million to $938 million -- the midpoint of that would be a 38% increase from Q2 2024. Its full-year guidance is now in a range from $3.89 billion to $3.902 billion. The main argument for investing in Palantir today, of course, is the valuation. With a trailing price-to-earnings ratio (P/E) of 682 and a forward P/E of 269, Palantir is ungodly expensive. But that's not a deal-breaker for me. I keep remembering that Amazon had a P/E of more than 1,000 back in 2013 before people realized how important cloud computing and its Amazon Web Services platform would be. I think Palantir is like Amazon -- people are just starting to appreciate that Palantir is a transformative company that is changing the world and how businesses and governments operate. And when it reports earnings on Aug. 4, I think you're going to continue to see the stock soar. How to invest in Palantir I would never recommend that someone overinvest in a stock or put their entire nest egg into Palantir. But I do think it's a company that should be part of a portfolio. If you are worried about the inherent volatility that comes with a stock that's growing as quickly as Palantir (and has such a crazy valuation), I recommend using a dollar-cost averaging strategy to establish your position over time. Just be sure never to be overextended on any one stock -- even one as compelling as Palantir. Should you buy stock in Palantir Technologies right now? Before you buy stock in Palantir Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Bank of America is an advertising partner of Motley Fool Money. Patrick Sanders has positions in Nvidia and Palantir Technologies. The Motley Fool has positions in and recommends Accenture Plc, Amazon, Apple, Microsoft, Nvidia, and Palantir Technologies. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. Palantir Stock Is Up 478% in a Year. Here's Why There's Still More Room to Run. was originally published by The Motley Fool Sign in to access your portfolio

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Yahoo

timean hour ago

  • Yahoo

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) ('Protara' or the 'Company'), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the recent grants of inducement non-qualified stock options and restricted stock units (RSUs) to two newly-hired employees. The Compensation Committee of Protara's Board of Directors approved an aggregate of 14,800 stock option awards and 7,400 RSU awards to two new employees from the Inducement Plan, as inducements material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Such option awards were granted on August 1, 2025 and have an exercise price of $3.06 per share, Protara's closing trading price on the grant date. Such RSU awards will have a grant date of October 1, 2025. All option awards vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the grant date and 1/36th of the underlying shares vesting monthly thereafter over 36 months. All RSU awards vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the grant date. The vesting of all option and RSU awards is subject to the employee's continued service with the company through the applicable vesting dates. About Protara Therapeutics, Inc. Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara's portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin (BCG), as well as a Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit Company Contact: Justine O'Malley Protara 646-817-2836 Source: Protara TherapeuticsSign in to access your portfolio

KORU Medical Systems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
KORU Medical Systems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Yahoo

timean hour ago

  • Yahoo

KORU Medical Systems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MAHWAH, N.J., August 01, 2025--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced inducement equity awards to Adam Kalbermatten, Chief Commercial Officer, pursuant to his previously announced employment agreement with the Company dated as of June 30, 2025. Mr. Kalbermatten was granted nonqualified stock options on August 1, 2025 to purchase 600,000 shares of the Company's common stock at an exercise price of $3.44 per share. In addition, on July 28, 2025, his start date, Mr. Kalbermatten received 300,000 restricted shares of the Company's common stock. Each of these awards are subject to vesting 25% on each anniversary of their grant date, subject to accelerated vesting and the other terms and conditions of the respective award agreements entered into between Mr. Kalbermatten and the Company. The Compensation Committee of the Company's Board of Directors approved the awards as an inducement material to Mr. Kalbermatten's employment in accordance with Nasdaq Listing Rule 5635(c)(4). About KORU Medical Systems KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world. The Freedom Syringe Infusion System (the "Freedom System") currently includes the Freedom60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HigH-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Pharma Services and Clinical Trials business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories. For more information, please visit View source version on Contacts Investor Contact: Louisa Smithinvestor@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store